Personalised medicine. Aims and challenges

被引:1
作者
Bieber, T. [1 ]
Broich, K. [2 ]
机构
[1] Univ Klinikum Bonn, Klin & Poliklin Dermatol & Allergol, D-53105 Bonn, Germany
[2] Bundesinst Arzneimittel & Med Prod, Bonn, Germany
关键词
Personalized medicine; Stratification; Biomarker; STRATIFIED MEDICINE; PRECISION MEDICINE; CANCER MEDICINE; OMICS; DIAGNOSTICS; BIOMARKERS; OUTLOOK; PROMISE; FUTURE; CARE;
D O I
10.1007/s00103-013-1841-z
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Personalised medicine will address the clinical and pathophysiologic complexity of many diseases with the aim of developing therapeutic strategies more adapted for selected individuals or patient subgroups in order to improve efficacy and safety of medicinal products. This biomarker-based approach will potentially allow identification of populations at risk for chronic and life-threatening diseases and to design early intervention strategies. Personalised medicine will lead to a substantial move from costly and often inefficient health care to a hopefully more cost effective, more targeted and more preventive approach addressing participative patients with increased health literacy. Thus, it provides the basement for an ultimate paradigm shift of modern medicine, away from a "reactive" medicine to a more "proactive" and personalised health care, so-called "P4 medicine".
引用
收藏
页码:1468 / 1472
页数:5
相关论文
共 38 条
  • [1] [Anonymous], 2012, WORKSH PHARM SCI CLI
  • [2] Personalized medicine in cytokine-targeted therapy
    Behrens, F.
    Koehm, M.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 (01): : 41 - +
  • [3] From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges
    Bianchi, Diana W.
    [J]. NATURE MEDICINE, 2012, 18 (07) : 1041 - 1051
  • [4] Bieber T., 2013, FUTURE MED, DOI [10.2217/9781780843186, DOI 10.2217/9781780843186]
  • [5] Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine
    Bieber, Th.
    [J]. ALLERGY, 2012, 67 (12) : 1475 - 1482
  • [6] Systems medicine and integrated care to combat chronic noncommunicable diseases
    Bousquet, Jean
    Anto, Josep M.
    Sterk, Peter J.
    Adcock, Ian M.
    Chung, Kian Fan
    Roca, Josep
    Agusti, Alvar
    Brightling, Chris
    Cambon-Thomsen, Anne
    Cesario, Alfredo
    Abdelhak, Sonia
    Antonarakis, Stylianos E.
    Avignon, Antoine
    Ballabio, Andrea
    Baraldi, Eugenio
    Baranov, Alexander
    Bieber, Thomas
    Bockaert, Joel
    Brahmachari, Samir
    Brambilla, Christian
    Bringer, Jacques
    Dauzat, Michel
    Ernberg, Ingemar
    Fabbri, Leonardo
    Froguel, Philippe
    Galas, David
    Gojobori, Takashi
    Hunter, Peter
    Jorgensen, Christian
    Kauffmann, Francine
    Kourilsky, Philippe
    Kowalski, Marek L.
    Lancet, Doron
    Le Pen, Claude
    Mallet, Jacques
    Mayosi, Bongani
    Mercier, Jacques
    Metspalu, Andres
    Nadeau, Joseph H.
    Ninot, Gregory
    Noble, Denis
    Ozturk, Mehmet
    Palkonen, Susanna
    Prefaut, Christian
    Rabe, Klaus
    Renard, Eric
    Roberts, Richard G.
    Samolinski, Boleslav
    Schuenemann, Holger J.
    Simon, Hans-Uwe
    [J]. GENOME MEDICINE, 2011, 3
  • [7] Brüggenjürgen B, 2012, BUNDESGESUNDHEITSBLA, V55, P710, DOI 10.1007/s00103-012-1479-2
  • [8] Creative trial design in RA: optimizing patient outcomes
    Buch, Maya H.
    Pavitt, Sue
    Parmar, Mahesh
    Emery, Paul
    [J]. NATURE REVIEWS RHEUMATOLOGY, 2013, 9 (03) : 183 - 194
  • [9] Bundesministerium fur Bildung und Forschung, 2013, AKT IND MED NEUER WE
  • [10] Omics-based clinical trial designs
    Buyse, Marc
    Michiels, Stefan
    [J]. CURRENT OPINION IN ONCOLOGY, 2013, 25 (03) : 289 - 295